Characterization of the adverse events profile of placebo-treated patients in randomized controlled trials on drug-resistant focal epilepsies

Journal of Neurology

Volumn 262, Issue 6, 2015, Pages 1401-1406

  Giovannelli, Fabio ^a,b   Zaccara, Gaetano ^a   Cincotta, Massimo ^a   Loiacono, Giulia ^c   Verrotti, Alberto ^d  

^a SAN GIOVANNI DI DIO HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

^d UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Adverse effects; Antiepileptic drugs; Epilepsy; Meta analysis; Meta regression; Nocebo effects; Placebo effects; Side effects

Indexed keywords

PLACEBO;

ATAXIA; ATTRIBUTABLE RISK; COORDINATION DISORDER; DIPLOPIA; DIZZINESS; DRUG EFFICACY; DRUG RESISTANT EPILEPSY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FOCAL EPILEPSY; HUMAN; NEUROLOGIC DISEASE; NOCEBO EFFECT; OUTCOME ASSESSMENT; PLACEBO EFFECT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOMNOLENCE; STUDY DESIGN; SYSTEMATIC REVIEW; TREMOR; BIBLIOGRAPHIC DATABASE; STATISTICS AND NUMERICAL DATA;

DATABASES, BIBLIOGRAPHIC; DRUG RESISTANT EPILEPSY; HUMANS; NOCEBO EFFECT; OUTCOME ASSESSMENT (HEALTH CARE); PLACEBO EFFECT; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84931008270     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-014-7535-0     Document Type: Review

References (30)

1. Murray D, Stoessl AJ (2013) Mechanisms and therapeutic implications of the placebo effect in neurological and psychiatric conditions. Pharmacol Ther 140:306–318
2. Perucca E (2012) What clinical trial designs have been used to test antiepileptic drugs and do we need to change them? Epileptic Disord 14:124–131
3. Enck P, Klosterhalfen S, Weimer K et al (2011) The placebo response in clinical trials: more questions than answers. Philos Trans R Soc Lond B Biol Sci 27(366):1889–1895
4. Colloca L, Miller FG (2011) The nocebo effect and its relevance for clinical practice. Psychosom Med 73:598–603
5. Amanzio M, Corazzini LL, Vase L, Benedetti F (2009) A systematic review of adverse events in placebo groups of anti-migraine clinical trials. Pain 146:261–269
6. Rief W, Nestoriuc Y, von Lilienfeld-Toal A et al (2009) Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis. Drug Saf 32:1041–1056
7. Papadopoulos D, Mitsikostas DD (2010) Nocebo effects in multiple sclerosis trials: a meta-analysis. Mult Scler 16:816–828
8. Mitsikostas DD, Mantonakis LI, Chalarakis NG (2011) Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches. Cephalalgia 31:550–561
9. Häuser W, Sarzi-Puttini P, Tölle TR, Wolfe F (2012) Placebo and nocebo responses in randomised controlled trials of drugs applying for approval for fibromyalgia syndrome treatment: systematic review and meta-analysis. Clin Exp Rheumatol 30(6 Suppl 74):78–87
10. Mitsikostas DD, Chalarakis NG, Mantonakis LI et al (2012) Nocebo in fibromyalgia: meta-analysis of placebo-controlled clinical trials and implications for practice. Eur J Neurol 19:672–680
11. Papadopoulos D, Mitsikostas DD (2012) A meta-analytic approach to estimating nocebo effects in neuropathic pain trials. J Neurol 259:436–447
12. Stathis P, Smpiliris M, Konitsiotis S, Mitsikostas DD (2013) Nocebo as a potential confounding factor in clinical trials for Parkinson’s disease treatment: a meta-analysis. Eur J Neurol 20:527–533
13. Guekht AB, Korczyn AD, Bondareva IB et al (2010) Placebo responses in randomized trials of antiepileptic drugs. Epilepsy Behav 17:64–69
14. Rheims S, Perucca E, Cucherat et al (2011) Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis. Epilepsia 52:219–233
15. Zaccara G, Giovannelli F, Cincotta M, Loiacono G, Verrotti A (2014) Adverse events of placebo-treated, drug-resistant, focal epileptic patients in randomized controlled trials: a systematic review. J Neurol [Epub ahead of print]
16. Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Open Med 3:e123–e130
17. Wallace BC, Schmid CH, Lau J et al (2009) Meta-Analyst: software for meta-analysis of binary, continuous and diagnostic data. BMC Med Res Methodol 9:80
18. Brinkhaus B, Pach D, Lüdtke R et al (2008) Who controls the placebo? Introducing a placebo quality checklist for pharmacological trials. Contemp Clin Trials 29:149–156
19. Zaccara G, Perucca P, Gangemi PF (2012) The adverse event profile of pregabalin across different disorders: a meta-analysis. Eur J Clin Pharmacol 68:903–912
20. Zaccara G, Perucca P, Loiacono G, Giovannelli F, Verrotti A (2013) The adverse event profile of lacosamide: a systematic review and meta-analysis of randomized controlled trials. Epilepsia 54:66–74
21. Benedetti F, Amanzio M (2013) Mechanisms of the placebo response. Pulm Pharmacol Ther 26:520–523
22. Benedetti F, Amanzio M (2011) The placebo response: how words and rituals change the patient’s brain. Patient Educ Couns 84:413–419
23. Levine ME, Stern RM, Koch KL (2006) The effects of manipulating expectations through placebo and nocebo administration on gastric tachyarrhythmia and motion-induced nausea. Psychosom Med 68:478–486
24. Liccardi G, Senna G, Russo M et al (2004) Evaluation of the nocebo effect during oral challenge in patients with adverse drug reactions. J Investig Allergol Clin Immunol 14:104–107
25. Flaten MA, Simonsen T, Olsen H (1999) Drug-related information generates placebo and nocebo responses that modify the drug response. Psychosom Med 61:250–255
26. Colloca L, Benedetti F (2006) How prior experience shapes placebo analgesia. Pain 124:126–133
27. Rosenthal R (1966) Experimenter effects in behavioral research. Appleton Century Crofts, New York
28. Golomb BA, McGraw JJ, Evans MA et al (2007) Physician response to patient reports of adverse drug effects. Drug Saf 80:669–678
29. Rief W, Avorn J, Barsky AJ (2006) Medication-attributed adverse effects in placebo groups: implications for assessment of adverse effects. Arch Intern Med 166:155–160
30. Ben-Menachem E, Gabbai AA, Hufnagel A et al (2010) Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilepsy Res 89:278–285